Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GoodRx

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective immediately.

Benzinga

Woman donates plasma for ‘extra money.’ Then she issues a warning about the unexpected side effect she’s experiencing

Donating plasma is one of the lesser known ways people can make some extra money without doing much. You just show up at a donation center, endure the prick of a needle, and collect some cash at the end.

The Mary Sue

If you have Medicare, here’s what you’ll pay for health care in 2025

The most significant Medicare change for 2025 will be the new $2,000 cap for prescription drugs.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals

GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024.

Benzinga

Charter Names Simon Cassels SVP, Chief Creative Officer

Cassels’ award-winning accomplishments include Apple’s “Shot on iPhone” campaign

TV Tech

Take a Mid-Year Review of Your Health Insurance Coverage

Whether it's monitoring your deductible or using a health savings account, here are the best ways to maximize use of your health insurance coverage

Kiplinger

3 Top Stocks Under $10 to Buy Instead of GameStop

Meme stocks such as GME and AMC have risen substantially this month. However, due to their weak fundamentals, these companies are high-risk investments.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Sempre Health's innovative approach improves medication adherence and lowers costs

Initiatives like GoodRx and Sempre Health are working towards transparency and affordability in the drug supply chain to improve medication adherence. Blue...

Top News

A popular asthma inhaler is leaving pharmacy shelves. Here's what you need to know

Flovent — a common asthma inhaler — will be discontinued in 2024. There will be a generic version available, but the change could make it hard for some patients to get their medication.

WEKU

Walgreens Launches Digital Tool To Help Save On Prescription Costs

Walgreens says its Rx Savings Finder will help customers compare coupon prices to get the best deal.

Kiplinger

Free prescription discount cards from GoodRx — What’s the catch?

GoodRx’s prescription savings program offers significant discounts on prescription drugs, but not without some catches

The Independent UK

3 Hot Stocks Under $10 for Your September Watchlist

These outperformers are all trading under $10 per share - for now. After beating the S&P 500 year-to-date, analysts think these standout single-digit stocks all have room to keep running higher.

Barchart

A fertility app with lots of leaks

The agency says the fertility app Premom deceived users about their data.

Fortune

Mark Cuban has been taking on the drug industry. But which one?

The billionaire entrepreneur is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Los Angeles Times

Editorial: FTC crackdown on GoodRx sends a message that private consumer data must be protected

Since 2017, GoodRx has helped millions of people find deals on prescription drugs via an app and website. But what its customers may not have known is that the Santa Monica-based health company had also been sharing information about their prescriptions and illnesses with third parties such as Google and…

The Independent UK

FTC fines GoodRx for unauthorized sharing of health data

The Federal Trade Commission has imposed a $1.5 million penalty on telehealth and prescription drug discount provider GoodRx Holdings Inc. for sharing users’ personal health data with Facebook, Google and other third parties without their consent

Chicago Sun-Times

Discount prescription company GoodRx fined $1.5 million for sharing sensitive user info

The FTC alleged the company shared info on users’ medication and illnesses for the purpose of targeted ads.

WEKU

Wegovy works. But here's what happens if you can't afford to keep taking the drug

The new weight-loss drugs can be life-changing for people facing health conditions worsened by obesity, but price and spotty insurance coverage may keep them out of reach.

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Climate change magnifies health impacts of wildfire smoke in care deserts

DRESSLERVILLE, Nev. — Smoke began billowing into the skies of northwestern Nevada in September, clouding the mountains, dimming the sun — and quashing residents’ hopes that they would be spared from wildfires and the awful air quality the blazes produce.

WEKU

5 things to know about the FDA's flawed approach to accelerated drug approvals

An NPR investigation found stalled confirmatory trials and lax enforcement are plaguing the FDA's accelerated approval of drugs for urgent medical needs.

WEKU

Drugmakers are slow to prove medicines that got a fast track to market really work

Stalled confirmatory trials and lax enforcement plague the Food and Drug Administration's accelerated approval pathway for pharmaceuticals that target urgent medical needs.

Benzinga

Baird Maintains Neutral Rating for GoodRx Holdings: Here's What You Need To Know

Baird has decided to maintain its Neutral rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $7.00 to $6.00. Shares of GoodRx Holdings are trading up 6.94% over the last 24 hours, at $6.32 per share. A move to $6.00 would account for a 5.06% decline from the…

Benzinga

Goldman Sachs Maintains Buy Rating for GoodRx Holdings: Here's What You Need To Know

Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00 to $12.00. Shares of GoodRx Holdings are trading up 1.32% over the last 24 hours, at $8.07 per share.

Benzinga

GoodRx Shares Tumble As FY22 Guidance Hit By Grocery Chain Prescription Dispute

GoodRx Holdings Inc (NASDAQ: GDRX) shares fell after it expects FY22 revenue to take a hit due to recent actions by one grocery store chain that represents a sizable chunk of its grocery prescription business.

The Independent UK

Can billionaire celebrity Mark Cuban fix America’s broken health system?

The celebrity investor has teamed up with a soft-spoken radiologist to tackle the USA’s healthcare crisis – and he has drug industry middlemen squarely in his sights, reports Io Dodds

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.